The existence of blood-brain barrier (BBB) greatly hindered the penetration and accumulation of chemotherapeutics into
glioblastoma (GBM), accompany with poor
therapeutic effects. The growth of GBM supervene the impairment of tight junctions (TJs); however, the pathogenesis of BBB breakdown in GBM is essentially poorly understood. This study found that
vascular endothelial growth factor (
VEGF) secreted by GBM cells plays an important role in increasing the permeability of BBB by disrupting endothelial
tight junction proteins claudin-5 and thus gave
doxorubicin (DOX)-loaded
glycolipid-like nanoparticles (Ap-CSSA/DOX), an effective entrance to
brain tumor region for GBM-targeting
therapy. In addition,
VEGF downregulates the expression of
claudin-5 with a dose-dependent mode, and interfering with the
VEGF/VEGFR pathway using its inhibitor
axitinib could reduce the permeability of BBB and enhance the integrity of the barrier. Ap-CSSA/DOX nanoparticles showed high affinity to expressed
low-density lipoprotein receptor-related
proteins 1 (LRP1) in both BBB and GBM. And BBB pathological fenestration in GBM further exposed more LRP1 binding sites for Ap-CSSA/DOX nanoparticles targeting to
brain tumor, resulting in a higher transmembrane transport ratio in vitro and a stronger
brain tumor biodistribution in vivo, and finally realizing a considerable antitumor effect. Overall, taking advantage of BBB pathological features to design an appropriate nanodrug delivery system (NDDS) might provide new insights into other central nervous system (
CNS) diseases treatment.